Annexon Inc (NAS:ANNX)
$ 5.39 0.05 (0.94%) Market Cap: 574.54 Mil Enterprise Value: 264.03 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 40/100

Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) Transcript

Mar 08, 2022 / 07:10PM GMT
Release Date Price: $4.65 (+6.90%)
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Welcome and good afternoon. Thanks, everybody, once again for joining us at the 42nd Annual Cowen Healthcare Conference. I'm Yaron Werber, one of the biotech analyst at Cowen. And it's a great pleasure to moderate the orphan CNS therapies panel with my colleagues, Brendan Smith and Lyla Youssef. We really have a terrific lineup today and a lot to talk about. We have from Annexon, Doug Love, who's the CEO; Geoff MacKay, who's the CEO of AVROBIO; we have Bobby Gaspar, who's the CEO of Orchard; Bruce Goldsmith, who's the CEO of Passage Bio; Emil Kakkis, who's the President and CEO of Ultragenyx; and Arnon Rosenthal, who is the CEO of Alector is going to be joining momentarily. So welcome, everybody, and thanks for joining us. We appreciate it.

So let's start. What we're going to do is we're going to talk first about a couple of maybe very broad drug development topics in orphan neurology, and then we'll do a round robin and dive into each company specifically. Most of you are developing drugs

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot